- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00455325
Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS) (ARCH-MS)
Genotoxic Stress, Atherosclerosis, and Metabolic Syndrome-AIM 2
Study Overview
Status
Detailed Description
Metabolic syndrome is one of the most common disorders in industrialized countries. It consists of abnormal serum lipids, glucose intolerance, elevated blood pressure, and central obesity in the setting of insulin resistance. The syndrome substantially increases the risk of developing diabetes and vascular disease, but there is no clear unifying approach to treat this disorder. In animals, activation of the protein ataxia telangiectasia mutated (ATM) using the antimalarial drug chloroquine improves features of metabolic syndrome and decreases atherosclerosis, a build-up of fatty plaque within arteries. The purpose of this study is to evaluate the effectiveness of short-term treatment with low doses of chloroquine as a way of managing metabolic syndrome.
Participants in this study will initially receive placebo for 3 weeks, followed by increasing doses of chloroquine in three, 3-week intervals. Following each 3-week treatment, participants will be admitted to the research center for one day. There will be a period of no active treatment for 5 to 7 weeks following each admission to the research center to allow recovery from the blood drawing of the clamp procedure before the start of the next treatment interval.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University in St. Louis
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Diagnosis of metabolic syndrome, as determined by at least three of the following five criteria:
- Elevated fasting triglyceride levels greater than or equal to 150 mg/dL
- Low HDL cholesterol levels: less than 50 mg/dL for women and less than 40 mg/dL for men
- Hypertension (=>130/85 mm Hg =<160/100 mm Hg) untreated; or hypertension controlled (=<150/90 mm Hg) on a stable medication regimen for 4 weeks prior to baseline visit.
- Increased waist circumference: greater than 35 inches in women and greater than 40 inches in men
- Elevated fasting glucose levels =<100 mg/dL but =>126 mg/dL
- Subjects may be on a stable doses of a statin drug for at least 3 months
- Subjects may be on a stable doses of L-thyroxine for at least 3 months
- Willing to use acceptable form of birth control (e.g., hormonal birth control, double barrier methods)
Exclusion Criteria:
Prior travel treatment with chloroquine or hydroxychloroquine as follows:
- any exposure in the past 2 years,
- >30 days of therapy if exposure was between 2 and 5 years ago,
- >90 days of therapy if exposure was between 5 and 10 years ago,
- >6 months of therapy if exposure was 10 to 20 years ago,
- >1 year of therapy if exposure was 20 to 30 years ago,
- No limit if last exposure was >30 years ago, ex. during the Vietnam conflict.
- Morbid obesity (body mass index [BMI] greater than 45)
- Coronary artery disease or other vascular disease
- History of stroke
- Chronic kidney insufficiency (i.e.,estimated glomerular filtration rate (eGFR) less than 60 ml/min/1.73m2)
- Diabetes
- Seizure disorder
- History of psoriasis
- Blood disorders, including anemia (i.e., hemoglobin levels less than 13 g/dL in men and less than 12 g/dL in women)
- Current malignancy or active treatment for recurrence prevention, example tamoxifen. Cancer considered to be cured, either as a result of surgery or other treatment is not exclusionary.
- Asthma requiring daily beta agonist therapy or intermittent oral steroids is exclusionary. Inhaled steroids are acceptable. Obstructive sleep apnea will be allowed if Continuous Positive Airway Pressure (CPAP) or other therapy has been stable for 6 months. Other active respiratory diseases are excluded.
- Liver disease, or liver function test results greater than twice the normal value
- Active infection, including HIV
- Serious illness requiring ongoing medical care or medication
- Treatment with atypical anti-psychotic medication. Treatment with any other medication for psychiatric illness, unless on a stable dose for 6 weeks prior to enrollment. Patients with unstable psychiatric disorders are excluded per the decision of the study MD regardless of medication history.
- Taking any of the following lipid lowering medications: niacin, fibrates, and greater than 1 gm fish oils
- Uncontrolled hypertension (BP >150/90) at enrollment.
- Need for daily over the counter medications, or currently taking cimetidine or >1000 IU vitamin E daily and unwilling to reduce or discontinue the use of vitamin E or discontinue cimetidine for the duration of the study. Persons taking >1000 IU of vitamin E should reduce the dose 30 days prior to randomization.
- Pregnant, breastfeeding, or intending to become pregnant
- Glucose-6-phosphate dehydrogenase (G6PD) deficiency
- Retinal disease (in particular, drusen or pigmentary changes at the macula); any ocular disease that interferes with the eye examination (e.g., cataracts)
- Auditory disease or hearing loss; persons with total, irreversible hearing loss can be enrolled.
- Participation in another clinical trial within past 30 days prior to screening and 60 days prior to randomization. Questionnaire or observational studies are not exclusionary.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: First Intervention (3 weeks)
Cohort 1: Chloroquine placebo one tablet daily for 3 weeks, followed by 5-7 week rest period.
|
once daily placebo tablet for 3 weeks followed by: euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells
Other Names:
|
Active Comparator: Second Intervention (3 weeks)
Cohort 2: 80mg chloroquine or placebo tablet once daily for Weeks 3, followed by 5-7 week rest period.
|
Once daily 80mg chloroquine or placebo tablet 3 Weeks followed by euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells
Other Names:
|
Active Comparator: Third Intervention (3 weeks)
Cohort 3: 80mg chloroquine tablet daily: for 3 weeks, followed by 5-7 week rest period.
|
Once daily 80mg tablet for 3 weeks followed by: euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells
Other Names:
|
Active Comparator: Fourth Intervention (3 weeks)
Cohort 4: 250mg chloroquine tablet daily: for 3 weeks, followed by 5-7 week rest period.
|
Once daily 250mg tablet for 3 weeks followed by: euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Insulin Sensitivity
Time Frame: assessed every 8 - 10 weeks at the end of each treatment period
|
Hepatic insulin sensitivity was measured by comparing glucose production at baseline of zero insulin infusion rate with glucose production at 56 pmol/m2/min.
Hepatic insulin sensitivity was expressed as the percent suppression, such that greater percent suppression indicated greater hepatic insulin sensitivity.
There are no reference values, since the patients served as their own controls.
|
assessed every 8 - 10 weeks at the end of each treatment period
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Systolic Blood Pressure
Time Frame: Assessed every 8-10 weeks at the end of each treatment period
|
Two techniques were employed: auscultation of seated subjects at rest was performed by a trained observer who recorded the first and fifth phases of the Korotkoff sounds; and, a portable oscillometric device (SpaceLabs Medical) recorded results every 20 min during the day and every hour during the night.
Data were analyzed as mean values over 24 hours.
|
Assessed every 8-10 weeks at the end of each treatment period
|
Diastolic Blood Pressure
Time Frame: Assessed every 8-10 weeks at the end of each treatment period.
|
Two techniques were employed: auscultation of seated subjects at rest was performed by a trained observer who recorded the first and fifth phases of the Korotkoff sounds; and, a portable oscillometric device (SpaceLabs Medical) recorded results every 20 min during the day and every hour during the night.
Data were analyzed as mean values over 24 hours.
|
Assessed every 8-10 weeks at the end of each treatment period.
|
Total Cholesterol
Time Frame: Assessed every 8-10 weeks at the end of each treatment period.
|
Fasting Serum Blood Sample
|
Assessed every 8-10 weeks at the end of each treatment period.
|
Non-HDL Cholesterol
Time Frame: Assessed every 8-10 weeks at the end of each treatment period.
|
Fasting Serum Blood Sample
|
Assessed every 8-10 weeks at the end of each treatment period.
|
Low-density Lipoprotein
Time Frame: Assessed every 8-10 weeks at the end of each treatment period.
|
Fasting Serum Blood Sample
|
Assessed every 8-10 weeks at the end of each treatment period.
|
Triglycerides
Time Frame: Assessed every 8-10 weeks at the end of each treatment period.
|
Fasting Serum Blood Sample
|
Assessed every 8-10 weeks at the end of each treatment period.
|
Collaborators and Investigators
Collaborators
Publications and helpful links
General Publications
- Schneider JG, Finck BN, Ren J, Standley KN, Takagi M, Maclean KH, Bernal-Mizrachi C, Muslin AJ, Kastan MB, Semenkovich CF. ATM-dependent suppression of stress signaling reduces vascular disease in metabolic syndrome. Cell Metab. 2006 Nov;4(5):377-89. doi: 10.1016/j.cmet.2006.10.002.
- McGill JB, Johnson M, Hurst S, Cade WT, Yarasheski KE, Ostlund RE, Schechtman KB, Razani B, Kastan MB, McClain DA, de Las Fuentes L, Davila-Roman VG, Ory DS, Wickline SA, Semenkovich CF. Low dose chloroquine decreases insulin resistance in human metabolic syndrome but does not reduce carotid intima-media thickness. Diabetol Metab Syndr. 2019 Jul 29;11:61. doi: 10.1186/s13098-019-0456-4. eCollection 2019.
- Razani B, Feng C, Semenkovich CF. p53 is required for chloroquine-induced atheroprotection but not insulin sensitization. J Lipid Res. 2010 Jul;51(7):1738-46. doi: 10.1194/jlr.M003681. Epub 2010 Mar 5.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Glucose Metabolism Disorders
- Metabolic Diseases
- Endocrine System Diseases
- Disease
- Diabetes Mellitus
- Body Weight
- Insulin Resistance
- Hyperinsulinism
- Lipid Metabolism Disorders
- Syndrome
- Metabolic Syndrome
- Prediabetic State
- Dyslipidemias
- Overweight
- Physiological Effects of Drugs
- Anti-Infective Agents
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antiprotozoal Agents
- Antiparasitic Agents
- Antimalarials
- Amebicides
- Filaricides
- Antinematodal Agents
- Anthelmintics
- Chloroquine
- Chloroquine diphosphate
Other Study ID Numbers
- 395
- P50HL083762 (NIH)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Addpharma Inc.Completed
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sulaiman AlRajhi CollegesUnknownHypertension, Essential | β-hydroxybutyrate
-
Centre Chirurgical Marie LannelongueUnknownChronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial HypertensionFrance
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
Clinical Trials on Placebo Comparator: First Intervention (3 weeks)
-
Olivier HugliUniversity of Lausanne HospitalsCompletedPain, Acute | Catheterization, PeripheralSwitzerland
-
University of WashingtonNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Emory... and other collaboratorsCompletedCardiovascular Disease | Sarcopenia | Endothelial Dysfunction | Kidney Disease | Muscle Mitochondrial FunctionUnited States
-
University of Alabama at BirminghamUniversity of Colorado, Denver; National Institute of Diabetes and Digestive... and other collaboratorsCompletedUrologicalUnited States, Canada
-
Hospital of South West JutlandNovo Nordisk A/SNot yet recruitingPhysical Activity | Postoperative Pain, Acute | Postoperative Pain, Chronic | Bariatric Surgery | MobilizationDenmark
-
Eisai Inc.CompletedHealthy | Drug AbuseCanada
-
Heidelberg UniversityWala GmbHCompletedDepression | Anxiety Disorders | MenopauseGermany
-
University of South FloridaFederal Emergency Management AgencyCompletedLow Back PainUnited States
-
Evandro Chagas Institute of Clinical ResearchNot yet recruitingChronic Chagas DiseaseBrazil
-
Merck Sharp & Dohme LLCCompleted
-
University of HullHull University Teaching Hospitals NHS TrustNot yet recruiting